Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Off-Label Reg Changes For Drugs Could Be Driven By Tobacco Policy

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA is eliminating ‘intended use’ regulation requiring firms to label products for unintended use when they have knowledge of such use.


Related Content

Swayed By Industry Opposition To 'Intended Use' Rule, FDA Definitively Delays Implementation
'Intended Use' Rule: US FDA May Toss Its 'Totality Of Evidence' Standard
Biopharma Wins Reprieve On US FDA 'Intended Use' Rule
US FDA Clarifies ‘Intended Use’ Policy For Approved Products


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts